Vertex Pharmaceuticals Patent-Cliff Exposure & CMS Drug Spending Portfolio

Vertex Pharmaceuticals (Boston, MA): 9 reconciled FDA prescription therapies (4.3% 2025 to 2030 cliff risk), $2.45B 2024 CMS Part D & Medicaid spend, and $2,200,000 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterBoston, MA
Reconciled FDA Portfolio Therapies9
2025 to 2030 Patent-Cliff Revenue Exposure4.3%
Primary Portfolio LOE Date2030-01-01
2024 CMS Total Public Spend$2.45B
2024 Medicare Part D Spend$770.5M
2024 Medicaid Spend$1.67B
California HCAI SB 17 FilingsSpecialty launch notice ($2,200,000 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Vertex Pharmaceuticals across sibling Meru public-data platforms.